CJC No DAC

What is it?

CJC no DAC, commonly called modified GRF (1–29), is a synthetic version of part of growth hormone–releasing hormone, or GHRH. It attracts interest for muscle growth, fat loss, recovery, and sleep because it targets the signals that control growth hormone. It is also sold in blends with ipamorelin. [1]

The name needs care. CJC-1295 with DAC is a different molecule with an added albumin-binding component. The familiar human CJC-1295 studies concern that long-acting form. Their results cannot simply be assigned to a no-DAC product. FDA specifically distinguishes the two. [1]

How does it work?

GHRH tells the pituitary gland to release growth hormone. CJC no DAC is designed to act through that signaling pathway. The proposed fitness benefits then depend on what the downstream hormone changes actually do in people.

Foundational CJC research demonstrated growth-hormone release in rat cells and rats using albumin-binding analogues. Those experiments helped explain the mechanism and development of CJC-1295 with DAC; they were not demonstrations of better recovery or muscle growth from no-DAC products in adults. [2]

What has human research found?

In two randomized, double-blind, placebo-controlled studies lasting 28 and 49 days, researchers tested long-acting CJC-1295 in healthy adults aged 21–61. After a single injection, mean growth hormone rose to roughly 2–10 times baseline for at least six days, and IGF-1 to about 1.5–3 times baseline for 9–11 days. These were hormone measurements, not demonstrated changes in muscle size, fat loss, sleep quality, or training recovery. [3]

Our focused search did not identify a controlled human trial establishing those fitness benefits for modified GRF (1–29) or for the specific CJC no DAC + ipamorelin blend. FDA's review also found that the available clinical CJC references appeared to involve the DAC form. [1]

Personal experiences can help identify questions worth studying, but a reported improvement cannot separate the peptide's effect from training, nutrition, other drugs, expectations, or normal recovery. Combining two ingredients also requires evidence for the combination; a result for either ingredient alone cannot establish the blend's benefit.

Safety and sport

CJC no DAC has no FDA-approved medicine or labeled fitness indication. FDA highlights potential immune reactions, peptide impurities, and difficulties confirming product identity. It also reports increased heart rate and systemic blood-vessel dilation reactions associated with CJC-1295. Those reports do not establish how frequently a particular no-DAC formulation causes harm. [1,4]

For tested athletes, WADA prohibits GHRH analogues and growth hormone secretagogues at all times, including CJC-1295 and ipamorelin. Removing DAC does not create an exemption from the GHRH-analogue category. [5]